Late filing
Filing comparison
ACURA PHARMACEUTICALS, INC told the SEC it could not file its quarterly report on time
The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 will not be filed within the prescribed time period because of the Company’s liquidity including the Company’s ability to meet day-to-day operation obligations. We continue to work on finding funding solutions and are dependent on the receipt of loans from Abuse Deterrent Pharma, LLC, which are used to meet day-to-day operation obligations, although no assurance can be made that the receipt of such loans will continue or be sufficient to meet long-term day-to-day operation obligations. We have not filed our Annual Reports for the year ended December 31, 2022, December 31, 2023, December 31, 2024 and…
Evidence
- Days past due date
- 12
- Routine
- No
- Severity
- normal
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 will not be filed within the prescribed time period because of the Company’s liquidity including the Company’s ability to meet day-to-day operation obligations. We continue to work on finding funding solutions and are dependent on the receipt of loans from Abuse Deterrent Pharma, LLC, which are used to meet day-to-day operation obligations, although no assurance can be made that the receipt of such loans will continue or be sufficient to meet long-term day-to-day operation obligations. We have not filed our Annual Reports for the year ended December 31, 2022, December 31, 2023, December 31, 2024 and…
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.